Endothelial progenitor cells: pathogenetic role and therapeutic perspectives
Alessandro Allegra1, Giuseppe Coppolino, Davide Bolignano
1Division of Hematology, University of Messina, Messina, Italy.
Journal of Nephrology
|August 8, 2009
Summary
Bone marrow-derived CD34+ progenitor cells show strong evidence for promoting tissue repair. These cells can differentiate into various cell types, contributing to both healing and disease pathogenesis.
Area of Science:
- Regenerative Medicine
- Cell Biology
- Hematology
Background:
- Bone marrow-derived CD34+ progenitor cells are recognized for their potential in tissue repair.
- These cells possess multipotent differentiation capabilities, including endothelial, hematopoietic, neuronal, fibroblast, and muscle lineages.
Purpose of the Study:
- To explore the role of CD34+ and AC133+ progenitor cells in neovascularization and tissue repair.
- To understand the dual role of these cells in both promoting healing and contributing to disease pathogenesis.
Main Methods:
- The study reviews existing evidence on the differentiation and homing of bone marrow-derived progenitor cells.
- Analysis of the participation of CD34+ and AC133+ cells in neovascularization and tissue remodeling.
Main Results:
- CD34+ and AC133+ progenitor cells can differentiate into endothelial cells, contributing to neovascularization.
- Circulating bone marrow-derived endothelial cells are recruited to injured tissues, aiding healing but also potentially promoting restenosis, tumor growth, and inflammation.
Conclusions:
- Bone marrow-derived progenitor cells play a significant role in tissue regeneration and disease pathogenesis.
- Further research is needed to elucidate the molecular mechanisms governing the homing and recruitment of these cells to remodeling tissues.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...